# MiraBiologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirabiologics

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.mirabiologics.com
- Total disclosed funding: $5M
- Latest round: Series A (Jan 15, 2020)
- Investors on record: 3

## About

MiraBiologics Inc. is a biopharmaceutical company focused on developing innovative Neobiologics using proprietary technology to address diverse therapeutic needs in global healthcare markets.Founded in 2017 and headquartered in Tokyo, Japan, MiraBiologics Inc. specializes in biopharmaceutical innovations. The company raised JPY 550 mn in SERIES A funding on January 15, 2020, from investors including SBI Investment, SMBC Venture Capital, and Shinsei Capital Partners. The total amount raised to date is JPY 550 mn, with a current company valuation of JPY 6,070.588 mn.MiraBiologics Inc. specializes in the development of innovative Neobiologics, which are multifunctional biopharmaceuticals created using their proprietary LassoGraft Technology®. This technology involves grafting target-specific cyclic peptides onto proteins in the body, thereby transforming these proteins into biologically active entities capable of addressing a range of therapeutic needs. The company's product offerings aim to extend the boundaries of biopharmaceuticals, catering to a diverse clientele that includes pharmaceutical companies and healthcare providers seeking advanced treatment options for various medical conditions. These offerings are designed to serve patients globally, with a focus on regions where there is a high demand for advanced therapies, including North America, Europe, and parts of Asia. The company's collaboration with pharmaceutical firms facilitates rapid development and distribution, ensuring that their Neobiologics reach the end-users who require them most.MiraBiologics Inc. operates on a partnership model that emphasizes collaboration with pharmaceutical companies to expedite the drug development process. Revenue generation occurs primarily through strategic alliances, leveraging its LassoGraft Technology® alongside the expertise of its partners in the biopharmaceutical sector. Transactions typically involve contractual agreements that may include performance milestones and co-development arrangements. While specific pricing information for their products and services is not disclosed, the company’s flagship offerings, which fall under the category of Neobiologics, are priced based on the complexity and uniqueness of the technology applied. The firm’s revenue structure supports both B2B interactions, focusing on partnerships with established pharmaceutical entities, and potentially direct-to-consumer channels as they expand their market reach.MiraBiologics Inc. plans to leverage its recent SERIES A funding of JPY 550 mn, raised on January 15, 2020, to enhance its research and development efforts. The company is focused on launching new Neobiologics and expanding into North America and Europe by 2022. This growth strategy will involve enhancing their LassoGraft Technology® to develop additional therapeutic products, ensuring they meet the rising demand for innovative biopharmaceutical solutions.

## Funding rounds

- Series A, Jan 15, 2020, $5M — SMBC Venture Capital, SBI Investment, Shinsei Capital Partners

## Investors

- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series A
- Shinsei Capital Partners (https://capitalatlas.ai/funds/shinsei-capital-partners) — Series A